IRX Therapeutics Names Mark Leuchtenberger President and CEO

Cancer immunotherapy developer IRX Therapeutics has appointed Mark Leuchtenberger president and CEO. John Hadden, founder and prior CEO of New York-based IRX, will remain a director of the company.

Leuchtenberger’s experience includes executive and senior management positions at Chiasma (NASDAQ: [[ticker:CHMA]]), Acusphere, Rib-X Pharmaceuticals, Therion Biologics, and Biogen (NASDAQ: [[ticker:BIIB]]). IRX also named Monil Shah chief operating officer. Shah was most recently medical affairs lead for immuno-oncology at Bristol-Myers Squibb (NYSE: [[ticker:BMY]]).

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan